{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:22:41Z","timestamp":1793996561364,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05495-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:45:58Z","timestamp":1767757558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes observed with Rivaroxaban versus low molecular weight heparin (Enoxaparin) for thrombo-prophylaxis following total knee arthroplasty: a meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yaxiong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"12","key":"5495_CR1","volume":"9","author":"PP Ratnasamy","year":"2025","unstructured":"Ratnasamy PP, Kaszuba SV, Maloy GC, Vasavada K, Vasudevan RS, Grauer JN, et al. Primary diagnoses associated with and outcomes of total knee arthroplasty in patients aged 15 to 45 years. J Am Acad Orthop Surg Glob Res Rev. 2025;9(12):e25.00198.","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"issue":"6","key":"5495_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1302\/0301-620X.89B6.18844","volume":"89","author":"D Warwick","year":"2007","unstructured":"Warwick D, Friedman RJ, Agnelli G, Gil-Garay EA, Johnson K, FitzGerald G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89(6):799\u2013807.","journal-title":"J Bone Joint Surg Br"},{"issue":"3","key":"5495_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.26502\/josm.511500210","volume":"7","author":"A Postajian","year":"2025","unstructured":"Postajian A, Rostomian E, Abdou A, Hatamian V, Keshishian S, Agrawal DK. Management of venous thromboembolism after hip and knee arthroplasty. J Orthopaedics Sports Med. 2025;7(3):311\u201327.","journal-title":"J Orthopaedics Sports Med"},{"issue":"2","key":"5495_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.knee.2019.01.004","volume":"26","author":"SS Richardson","year":"2019","unstructured":"Richardson SS, Schairer WW, Sculco PK, Bostrom MP. Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty. Knee. 2019;26(2):451\u20138.","journal-title":"Knee"},{"key":"5495_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.775126","volume":"12","author":"YH Yi","year":"2022","unstructured":"Yi YH, Gong S, Gong TL, Zhou LY, Hu C, Xu WH. New oral anticoagulants for venous thromboembolism prophylaxis in total hip and knee arthroplasty: a systematic review and network meta-analysis. Front Pharmacol. 2022;12:775126.","journal-title":"Front Pharmacol"},{"issue":"4","key":"5495_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.amjmed.2015.10.022","volume":"129","author":"PD Stein","year":"2016","unstructured":"Stein PD, Matta F, Hughes MJ. Home treatment of deep venous thrombosis according to comorbid conditions. Am J Med. 2016;129(4):392\u20137.","journal-title":"Am J Med"},{"issue":"5","key":"5495_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.thromres.2015.02.008","volume":"135","author":"G Ma","year":"2015","unstructured":"Ma G, Zhang R, Wu X, Wang D, Ying K. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: a meta-analysis of 6 randomized clinical trials. Thromb Res. 2015;135(5):816\u201322.","journal-title":"Thromb Res"},{"issue":"9","key":"5495_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014539","volume":"98","author":"J Liu","year":"2019","unstructured":"Liu J, Zhao J, Yan Y, Su J. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(9):e14539.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"5495_CR9","doi-asserted-by":"publisher","DOI":"10.1590\/0100-6991e-20192075","volume":"46","author":"RR Rodarte","year":"2019","unstructured":"Rodarte RR, Guimar\u00e3es JA, Franco JS, Fonseca L, Nascimento V, Aramburu JP, et al. Systematic review of prophylaxis for venous thromboembolism after knee arthroplasty: enoxaparin versus rivaroxaban. Rev Col Bras Cir. 2019;46(2):e2075.","journal-title":"Rev Col Bras Cir"},{"key":"5495_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"9","key":"5495_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"5495_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"26","key":"5495_CR13","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776\u201386.","journal-title":"N Engl J Med"},{"key":"5495_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/VHRM.S54714","volume":"10","author":"B Levitan","year":"2014","unstructured":"Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014;10:157\u201367.","journal-title":"Vasc Health Risk Manag"},{"key":"5495_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/TCRM.S129077","volume":"13","author":"P Liu","year":"2017","unstructured":"Liu P, Liu J, Chen L, Xia K, Wu X. Intermittent pneumatic compression devices combined with anticoagulants for prevention of symptomatic deep vein thrombosis after total knee arthroplasty: a pilot study. Ther Clin Risk Manag. 2017;13:179\u201383.","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"5495_CR16","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","volume":"3","author":"AGG Turpie","year":"2005","unstructured":"Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, K\u00e4lebo P, et al. BAY 59\u20137939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11):2479\u201386.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5495_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1160\/TH08-07-0460","volume":"101","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68\u201376.","journal-title":"Thromb Haemost"},{"issue":"9676","key":"5495_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673\u201380.","journal-title":"Lancet"},{"key":"5495_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.12659\/MSM.900059","volume":"23","author":"J Xie","year":"2017","unstructured":"Xie J, Ma J, Huang Q, Yue C, Pei F. Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study. Med Sci Monit. 2017;23:704\u201311.","journal-title":"Med Sci Monit"},{"issue":"4","key":"5495_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/2319-4170.125627","volume":"37","author":"SH Yen","year":"2014","unstructured":"Yen SH, Lin PC, Kuo FC, Wang JW. Thromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparin. Biomed J. 2014;37(4):199\u2013204.","journal-title":"Biomed J"},{"issue":"7","key":"5495_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","volume":"25","author":"Y Zou","year":"2014","unstructured":"Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis. 2014;25(7):660\u20134.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"5495_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"MM Samama","year":"2011","unstructured":"Samama MM. The mechanism of action of rivaroxaban\u2013an oral, direct Factor Xa inhibitor\u2013compared with other anticoagulants. Thromb Res. 2011;127(6):497\u2013504.","journal-title":"Thromb Res"},{"issue":"12","key":"5495_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","volume":"42","author":"J Fareed","year":"2003","unstructured":"Fareed J, Hoppensteadt D, Walenga J, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet. 2003;42(12):1043\u201357.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"5495_CR24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.29271\/jcpsp.2025.10.1318","volume":"35","author":"H He","year":"2025","unstructured":"He H, Yin Y, Xu X, Zhong Z. Rivaroxaban vs. enoxaparin for preventing venous thromboembolism and wound complications after knee surgery: a meta-analysis. J Coll Physicians Surg Pak. 2025;35(10):1318\u201324.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"10","key":"5495_CR25","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.asjsur.2024.02.113","volume":"47","author":"K Ding","year":"2024","unstructured":"Ding K, Yan W, Zhang Y, Li J, Li C, Liang C. The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: a systemic review and meta-analysis. Asian J Surg. 2024;47(10):4260\u201370.","journal-title":"Asian J Surg"},{"issue":"11","key":"5495_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","volume":"66","author":"YB Cao","year":"2010","unstructured":"Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66(11):1099\u2013108.","journal-title":"Eur J Clin Pharmacol"},{"key":"5495_CR27","doi-asserted-by":"crossref","unstructured":"Lazo-Langner A,\u00a0Fleet JL,\u00a0McArthur E, Garg\u00a0AX. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. J Thromb Haemost.\u00a02014;12(10):1626\u201335.","DOI":"10.1111\/jth.12675"},{"issue":"7","key":"5495_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1308\/rcsann.2016.0197","volume":"98","author":"V Loganathan","year":"2016","unstructured":"Loganathan V, Hua A, Patel S, Gibbons C, Vizcaychipi MP. Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study. Ann R Coll Surg Engl. 2016;98(7):507\u201315.","journal-title":"Ann R Coll Surg Engl"},{"issue":"1","key":"5495_CR29","volume":"1","author":"CA Salazar","year":"2025","unstructured":"Salazar CA, Flores JE, Malaga G, Malasquez GN, Bernardo R. Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair. Cochrane Database Syst Rev. 2025;1(1):CD011762.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"5495_CR30","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE\u2010MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178\u201385.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"5495_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14552","volume":"75","author":"M Ali Hasan","year":"2021","unstructured":"Ali Hasan M, Azeez Alsaadi M, Tahseen Mehsen J. Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: a retrospective study. Int J Clin Pract. 2021;75(10):e14552.","journal-title":"Int J Clin Pract"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05495-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:28:32Z","timestamp":1770204512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05495-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5495"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05495-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethical approval was not needed for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}